HPV in Head and Neck Cancer: Diagnosis

2012 ◽  
Vol 23 (1) ◽  
pp. 17-26
Author(s):  
Yuh-S. Jung
2018 ◽  
Vol 8 (1) ◽  
Author(s):  
P. Vohra ◽  
P. Strobbia ◽  
H. T. Ngo ◽  
W. T. Lee ◽  
T. Vo-Dinh

2019 ◽  
Vol 132 ◽  
pp. 82
Author(s):  
C. Talani ◽  
L. Farnebo ◽  
A. Mäkitie ◽  
G. Laurell

2006 ◽  
Vol 135 (2_suppl) ◽  
pp. P49-P49
Author(s):  
Ramez George Nassif ◽  
Paul Joice ◽  
Andrew Stewart Evans ◽  
Ah-See Kim ◽  
Simon Ogsten

2020 ◽  
Vol 23 (1) ◽  
Author(s):  
Antti Mäkitie ◽  
Iida Tuokkola ◽  
Göran Laurell ◽  
Outi Mäkitie ◽  
Kerry Olsen ◽  
...  

Abstract Purpose of review Observational studies have shown that serum 25-OH vitamin D [25(OH)D] is inversely associated with overall cancer risk in many malignancies. We performed a systematic literature review to determine whether vitamin D deficiency is related to head and neck cancer (HNC) etiology and outcome. Recent findings The search yielded five prospective studies reporting 25(OH)D levels prior to cancer diagnosis and their effect on the risk of HNC. Eight studies were cross-sectional or case-control studies, in which 25(OH)D levels were only measured after cancer diagnosis. Two studies found an inverse association between 25(OH)D level and HNC risk, while two other prospective cohort studies demonstrated no connection between 25(OH)D and HNC risk. Several studies reported cancer patients to have significantly lower 25(OH)D levels than controls. Associations between 25(OH)D and prognosis and mortality were variable. Summary The link between vitamin D and HNC has so far only been investigated in a few observational, prospective, and case-control studies. Vitamin D deficiency may be more common in HNC patients than in the healthy population. There is no evidence for a causal relationship. Further studies are needed to evaluate whether low 25(OH)D concentrations play a role in the development or outcome of HNCs.


2017 ◽  
Vol 35 (5_suppl) ◽  
pp. 137-137
Author(s):  
Daisuke Kawakita ◽  
Sarah Abdelaziz ◽  
Yuji Chen ◽  
Kerry G. Rowe ◽  
Yuan Wan ◽  
...  

137 Background: Sites of head and neck are associated with chewing, swallowing and speaking. As for treatment of head and neck cancer (HNC), we have to consider organ preservation as well as clinical outcomes. Although non-surgical treatments have been preferred in recent years, complications after treatment have been a concern. The aim of this study was to evaluate the late effects in a cohort of HNC survivors in Utah compared to a matched cohort of cancer free individuals. Methods: Up to 5 cancer free individuals were matched to each HNC survivor on birth year, sex, birth state, and follow up time. Electronic medical records and statewide ambulatory and inpatient surgery data were used to identify late effects over two time periods: 1-5 and 5-10 years after cancer diagnosis. Cox proportional hazards models were used to estimate the risks of late effects. We adjusted for matching factors, race and number of hospital visit. Results: In this study, 2,432 HNC survivors and 12,149 matched controls were enrolled. More than 80% cases had loco-regional disease and a histological type of squamous cell carcinoma. Hazard ratio (HR) for second primary HNC was notably increased among HNC survivors for both 1-5 years (HR: 1498.46; 95% confidence interval (CI), 158.58-14159.69) and 5-10 years (HR: 1509.62; 95% CI, 147.94-15404.15) post cancer diagnosis. And, HRs for respiratory disease, including respiratory system, lung cancer and pneumoniae, were also increased among HNC survivors for both 1-5 years and 5-10 years post cancer diagnosis. As for hearing loss, HNC survivors had a increased HR for 1-5 years post cancer diagnosis (HR: 5.90; 95% CI, 2.67-13.01) and this association was consistent for 5-10 years post cancer diagnosis (HR: 5.01; 95% CI, 2.06-12.18). Conclusions: In this study, we found HNC survivors have notable associations with second primary HNC, smoking related respiratory disease, and hearing loss which might be associated with chemotherapy when compared to cancer free subjects.


Oral Oncology ◽  
2018 ◽  
Vol 77 ◽  
pp. 137
Author(s):  
Pablo Varela-Centelles ◽  
José M. García-Martín ◽  
Juan Seoane-Romero

Dental Update ◽  
2019 ◽  
Vol 46 (9) ◽  
pp. 817-824
Author(s):  
Stephanie Hackett ◽  
Oliver Jones ◽  
Despoina Chatzistavrianou ◽  
David Newsum

This is the second paper in a three-part series to discuss head and neck cancer diagnosis, treatment and rehabilitation. Following a confirmed diagnosis of head and neck cancer, patients will begin a long and often challenging pathway that will involve clinicians from a multidisciplinary team (MDT). This paper will summarize the role of individual MDT members involved in patient care, diagnostic and treatment phases for head and neck cancer and common side-effects encountered. By gaining an insight into this part of the patient's journey, dental practitioners should feel more comfortable and confident engaging in the care and support for head and neck cancer patients. CPD/Clinical Relevance: This paper aims to provide readers with an insight into the journey that patients will undertake after being diagnosed with head and neck cancer.


Oral Oncology ◽  
2021 ◽  
Vol 115 ◽  
pp. 105211
Author(s):  
Angelina M.M. Santoso ◽  
Femke Jansen ◽  
Birgit I. Lissenberg-Witte ◽  
Robert J. Baatenburg de Jong ◽  
Johannes A. Langendijk ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document